¼¼°èÀÇ ½Å°æ Áø´Ü ½ÃÀå
Neurodiagnostics
»óǰÄÚµå : 1659306
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 89 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ½Å°æ Áø´Ü ½ÃÀåÀº 2030³â±îÁö 137¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 93¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µÇ´Â ½Å°æ Áø´Ü ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 6.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 137¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿µ»ó Áø´Ü ½Ã½ºÅÛÀº CAGR 6.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 90¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ü¿ÜÁø´Ü(IVD) ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR 6.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 24¾ï ´Þ·¯, Áß±¹Àº CAGR 9.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Å°æ Áø´Ü ½ÃÀåÀº 2024³â¿¡ 24¾ï ´Þ·¯¿¡ À̸¥ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 32¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGRÀº 9.7%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.6%¿Í 5.9%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½Å°æ Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ¼ºÀå ÃËÁø¿äÀÎ Á¤¸®

½Å°æ Áø´ÜÀº ½Å°æ Áúȯ °ËÃâ¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿Ã °ÍÀΰ¡?

½Å°æÁø´Ü¿¡´Â ³ú, ½Å°æ, ô¼öÀÇ Àå¾Ö¸¦ Áø´ÜÇϱâ À§ÇÑ ´Ù¾çÇÑ ±â¼ú°ú °Ë»ç°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ³úÆÄ °Ë»ç(EEG), ÀÚ±â°ø¸í¿µ»ó(MRI), ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT) ½ºÄµ, ½Å°æÀüµµ °Ë»ç µîÀÇ ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Áø´Ü µµ±¸¸¦ ÅëÇØ ÀÇ·á Àü¹®°¡´Â °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ³úÁ¹Áß, ´Ù¹ß¼º °æÈ­Áõ°ú °°Àº Áúº´À» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Å°æ ÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î È®»êµÊ¿¡ µû¶ó °í±Þ ½Å°æ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Áø´Ü ±â¼ú·ÎÀÇ ÀüȯÀº ÀÓ»ó°ú ¿¬±¸ ºÐ¾ß ¸ðµÎ¿¡¼­ ½Å°æ Áø´ÜÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½Å°æ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®Àº?

ÁÖ¿ä À¯ÇüÀ¸·Î´Â ¿µ»óÁø´Ü(MRI, CT ½ºÄµ), Àü±â»ý¸®ÇÐ(EEG, EMG), ü¿ÜÁø´Ü(¹ÙÀÌ¿À¸¶Ä¿, À¯ÀüÀÚ °Ë»ç)ÀÌ ÀÖ½À´Ï´Ù. ¿µ»óÁø´ÜÀº ½Å°æ°è¿¡ ´ëÇÑ »ó¼¼ÇÑ ±¸Á¶Àû, ±â´ÉÀû ÅëÂû·ÂÀ» Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ½Å°æ Áø´ÜÀÇ ¿ëµµ¿¡´Â Áúº´ Áø´Ü, Ä¡·á ¸ð´ÏÅ͸µ, ¿¬±¸ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÁÖ¿ä ÃÖÁ¾ »ç¿ëÀڷδ º´¿ø, Áø´Ü¼¾ÅÍ, ½Å°æ°ú Ŭ¸®´Ð, ¿¬±¸±â°ü µîÀÌ ÀÖÀ¸¸ç, Á¤È®ÇÑ Áø´Ü°ú Ä¡·á °èȹÀ» À§ÇØ ½Å°æÁø´ÜÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

½Å°æ Áø´ÜÀº ÀÇ·á ½Ã½ºÅÛ¿¡ ¾î¶»°Ô ÅëÇյǾî Àִ°¡?

º´¿øÀº ½Å°æ Áø´Ü µµ±¸ÀÇ ÁÖ¿ä »ç¿ëÀÚÀ̸ç, ÀÀ±Þ ¹× ÀÏ»óÀûÀÎ ½Å°æÇÐÀû Æò°¡¿¡ ¸ðµÎ »ç¿ëµË´Ï´Ù. Áø´Ü¼¾ÅÍ´Â ¿Ü·¡ ȯÀÚ Áø·á¿¡ ƯȭµÈ ½Å°æ Áø´Ü ¼­ºñ½º¸¦ Á¦°øÇϰí, ½Å°æ Ŭ¸®´ÐÀº °£Áú ¹× ÆÄŲ½¼º´°ú °°Àº ÁúȯÀÇ Àå±âÀûÀÎ ¸ð´ÏÅ͸µ¿¡ ÀÌ·¯ÇÑ µµ±¸¸¦ »ç¿ëÇÕ´Ï´Ù. ¿¬±¸±â°ü¿¡¼­´Â ½Å°æÁúȯÀÇ º´ÀÎ ¹× ÁøÇà ¿¬±¸¿¡ ½Å°æÁø´ÜÀ» Ȱ¿ëÇÏ¿© »õ·Î¿î Ä¡·á¹ý ¹× Ä¡·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á Ç÷§ÆûÀº ¿ø°Ý Áø·á¸¦ À§ÇØ ½Å°æ Áø´ÜÀ» ÅëÇÕÇϱ⠽ÃÀÛÇßÀ¸¸ç, ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ Áø´Ü ¼­ºñ½º¸¦ º¸´Ù ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

½Å°æ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

½Å°æ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº Á¶±â ¹ß°ß°ú È¿°úÀûÀÎ °ü¸®¸¦ À§ÇØ Ã·´Ü Áø´Ü µµ±¸°¡ ÇÊ¿äÇÑ ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿µ»óÁø´Ü ¹× Àü±â»ý¸®ÇÐÀÇ ±â¼ú ¹ßÀüÀ¸·Î Áø´Ü Á¤È®µµ°¡ Çâ»óµÇ¸é¼­ ÀÌ·¯ÇÑ µµ±¸´Â ÀÓ»ó ÇöÀå¿¡¼­ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í Ç¥Àû Ä¡·áÀÇ ºÎ»óµµ Áúº´ º´Å¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇϱ⠶§¹®¿¡ ½Å°æ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ÇコÄɾî ÀÎÇÁ¶ó¸¦ °­È­ÇÏ°í ½Å°æÇÐ ¿¬±¸¸¦ À§ÇÑ ÀÚ±ÝÀ» ´Ã¸®±â À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ È®´ë·Î ÀÎÇØ ÈÞ´ë°¡ °£ÆíÇϰí Á¢±ÙÇϱ⠽¬¿î ½Å°æ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(Áø´Ü ¿µ»ó ½Ã½ºÅÛ, ü¿Ü Áø´Ü(IVD)); »óÅÂ(½Å°æ ÅðÇ༺ Áúȯ, °£Áú, ³úÁ¹Áß, µÎÅë Àå¾Ö, ¼ö¸é Àå¾Ö, ±âŸ Áúȯ); ÃÖÁ¾ ¿ëµµ(Áø´Ü ½ÇÇè½Ç ¹× ¿µ»ó ¼¾ÅÍ, º´¿ø ¹× ¼ö¼ú ¼¾ÅÍ, ½Å°æ°ú ¼¾ÅÍ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 33°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Neurodiagnostics Market to Reach US$13.7 Billion by 2030

The global market for Neurodiagnostics estimated at US$9.3 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Diagnostic Imaging Systems, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$9.0 Billion by the end of the analysis period. Growth in the In-vitro diagnostics (IVD) segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 9.7% CAGR

The Neurodiagnostics market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.2 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 5.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neurodiagnostics Market - Key Trends and Drivers Summarized

How Is Neurodiagnostics Revolutionizing Neurological Disorder Detection?

Neurodiagnostics encompasses a range of technologies and tests used to diagnose disorders of the brain, nerves, and spinal cord. It includes techniques such as electroencephalography (EEG), magnetic resonance imaging (MRI), computed tomography (CT) scans, and nerve conduction studies, among others. These diagnostic tools enable healthcare professionals to identify conditions such as epilepsy, Alzheimer’s disease, Parkinson’s disease, stroke, and multiple sclerosis. As neurological disorders become more prevalent worldwide, the demand for advanced neurodiagnostic tools has grown significantly. The shift toward non-invasive diagnostic techniques has further propelled the adoption of neurodiagnostics in both clinical and research settings.

What Are The Key Segments in the Neurodiagnostics Market?

Major types include imaging modalities (MRI, CT scans), electrophysiology (EEG, EMG), and in vitro diagnostics (biomarkers, genetic testing). Imaging modalities hold a significant share due to their ability to provide detailed structural and functional insights into the nervous system. Applications of neurodiagnostics include disease diagnosis, treatment monitoring, and research. Key end-users include hospitals, diagnostic centers, neurology clinics, and research institutions, all of which rely on neurodiagnostics for accurate diagnosis and treatment planning.

How Is Neurodiagnostics Being Integrated Across Healthcare Systems?

Hospitals are major users of neurodiagnostic tools, employing them for both emergency and routine neurological assessments. Diagnostic centers offer specialized neurodiagnostic services for outpatient care, while neurology clinics use these tools for long-term monitoring of conditions like epilepsy and Parkinson’s disease. Research institutions utilize neurodiagnostics to study the etiology and progression of neurological disorders, contributing to new treatments and therapies. Additionally, telemedicine platforms are beginning to integrate neurodiagnostics for remote consultations, making diagnostic services more accessible, especially in underserved regions.

What Factors Are Driving the Growth in the Neurodiagnostics Market?

The growth in the neurodiagnostics market is driven by several factors, including the increasing prevalence of neurological disorders, which necessitates advanced diagnostic tools for early detection and effective management. Technological advancements in imaging and electrophysiology have improved diagnostic accuracy, making these tools indispensable in clinical practice. The rise of personalized medicine and targeted therapies has also boosted the demand for neurodiagnostics, as they provide crucial insights into disease pathology. Government initiatives to enhance healthcare infrastructure and increase funding for neurological research are further contributing to market growth. Additionally, the expansion of telehealth services has increased the demand for portable and accessible neurodiagnostic tools.

SCOPE OF STUDY:

The report analyzes the Neurodiagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Diagnostic Imaging Systems, In-vitro diagnostics (IVD)); Condition (Neuro Degenerative Diseases, Epilepsy, Stroke, Headache Disorders, Sleep Disorders, Other Conditions); End-Use (Diagnostic Laboratories & Imaging Centers, Hospitals & Surgery Centers, Neurology Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â